Management of Fibrosis: The Mesenchymal Stromal Cells Breakthrough
Fibrosis is the endpoint of many chronic inflammatory diseases and is defined by an abnormal accumulation of extracellular matrix components. Despite its slow progression, it leads to organ malfunction. Fibrosis can affect almost any tissue. Due to its high frequency, in particular in the heart, lun...
Saved in:
| Main Authors: | Benoît Usunier, Marc Benderitter, Radia Tamarat, Alain Chapel |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2014/340257 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-Term Quantitative Biodistribution and Side Effects of Human Mesenchymal Stem Cells (hMSCs) Engraftment in NOD/SCID Mice following Irradiation
by: Sabine François, et al.
Published: (2014-01-01) -
Mesenchymal stromal cell-derived membrane particles suppress kidney fibrosis
by: Shengbing Li, et al.
Published: (2025-07-01) -
Mesenchymal Stem/Stromal Cells in Stromal Evolution and Cancer Progression
by: Francesca Cammarota, et al.
Published: (2016-01-01) -
Osteosarcoma Cells and Undifferentiated Human Mesenchymal Stromal Cells Are More Susceptible to Ferroptosis than Differentiated Human Mesenchymal Stromal Cells
by: Yuliya D. Smirnova, et al.
Published: (2025-02-01) -
Mesenchymal Stem/Stromal Cells Microencapsulation for Cell Therapy
by: Sharaf Eldeen M. Abbas, et al.
Published: (2025-01-01)